-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200

Benzinga·07/21/2026 13:49:56
Listen to the news
Guggenheim analyst Brad Canino maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $175 to $200.